Lanean...
The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years
Acute myelogenous leukemia (AML) is primarily a disease of the elderly, and as such, our approach to treatment needs to be tailored to address an aging population. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for intermediate and high...
Gorde:
| Argitaratua izan da: | Blood Rev |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205157/ https://ncbi.nlm.nih.gov/pubmed/28802907 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.blre.2017.07.002 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|